Resumption of Illumina Royalty Payment Announced
Financial analysts have noted the upcoming resumption of a royalty payment to Illumina, which is expected to impact future gross margins.
Stocks · News reference
Evercore ISI Group reaffirmed its 'Outperform' rating on Illumina while adjusting its price target to $275 from $290.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Financial analysts have noted the upcoming resumption of a royalty payment to Illumina, which is expected to impact future gross margins.
Baird has updated its outlook on Illumina, maintaining a 'Hold' rating while increasing the price target to $236.
Illumina has been selected to contribute to initiatives aimed at integrating precision medicine into everyday healthcare services in Singapore.
Citigroup has maintained its "Sell" rating on Illumina, Inc. while increasing the price target from $113 to $210.
Alphabet logs its worst week since 2011 and Intel its worst day ever as the AI trade cracks, while health care posts a record month against the market.
JPMorgan has revised its price target for Illumina, Inc. (NASDAQ: ILMN), lowering it from $320 to $300.